Structure Therapeutics (GPCR)
Structure Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
7.1M
Short interest
settlement 2026-10-15
4.8
Days to cover
-0.4 days vs prior
58.4%
Short share of volume
2026-11-03
3,299
Fails to deliver
settlement 2026-10-14
Thu 5 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-03.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in GPCR is 7,147,328 shares, up 542,317 shares over the last month. Over the last 48 readings it ranged from 4,809,347 shares (28 November 2025) to 11,233,314 shares (15 November 2024). At the reported average volume of 1.5M shares a day that is 4.8 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/gpcr" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 7,147,328 | -5.2% | 1,497,742 | 4.77 |
| 2026-09-30 | 7,540,480 | +14.2% | 1,458,682 | 5.17 |
| 2026-09-15 | 6,605,011 | +12.8% | 1,262,278 | 5.23 |
| 2026-08-31 | 5,854,907 | -3.7% | 740,185 | 7.91 |
| 2026-08-14 | 6,079,970 | +0.5% | 585,763 | 10.38 |
| 2026-07-31 | 6,049,938 | -2.5% | 528,506 | 11.45 |
| 2026-07-15 | 6,206,238 | +1.3% | 703,317 | 8.82 |
| 2026-06-30 | 6,127,886 | +4.0% | 978,055 | 6.27 |
| 2026-06-15 | 5,893,905 | +5.8% | 826,251 | 7.13 |
| 2026-05-29 | 5,572,394 | -1.4% | 618,035 | 9.02 |
| 2026-05-15 | 5,651,873 | -5.4% | 770,632 | 7.33 |
| 2026-04-30 | 5,972,579 | -2.8% | 884,058 | 6.76 |
| 2026-04-15 | 6,147,220 | +6.8% | 1,013,855 | 6.06 |
| 2026-03-31 | 5,756,688 | +9.4% | 1,219,497 | 4.72 |
| 2026-03-13 | 5,263,638 | +0.6% | 742,100 | 7.09 |
| 2026-02-27 | 5,231,721 | +6.1% | 750,990 | 6.97 |
| 2026-02-13 | 4,932,545 | -3.9% | 1,015,941 | 4.86 |
| 2026-01-30 | 5,133,106 | -17.8% | 1,070,048 | 4.80 |
| 2026-01-15 | 6,246,481 | +3.3% | 1,312,267 | 4.76 |
| 2025-12-31 | 6,044,599 | +23.7% | 1,105,707 | 5.47 |
| 2025-12-15 | 4,887,952 | +1.6% | 3,311,398 | 1.48 |
| 2025-11-28 | 4,809,347 | -9.0% | 1,512,796 | 3.18 |
| 2025-11-14 | 5,283,748 | -1.4% | 985,313 | 5.36 |
| 2025-10-31 | 5,358,871 | +10.5% | 765,920 | 7.00 |
| 2025-10-15 | 4,848,935 | -23.9% | 1,088,504 | 4.45 |
| 2025-09-30 | 6,369,685 | -6.3% | 1,056,411 | 6.03 |
| 2025-09-15 | 6,796,004 | -2.1% | 1,624,779 | 4.18 |
| 2025-08-29 | 6,938,872 | -4.4% | 586,571 | 11.83 |
| 2025-08-15 | 7,255,119 | +0.9% | 1,068,265 | 6.79 |
| 2025-07-31 | 7,191,093 | -8.5% | 734,402 | 9.79 |
| 2025-07-15 | 7,856,296 | +7.2% | 690,279 | 11.38 |
| 2025-06-30 | 7,326,465 | -11.4% | 730,055 | 10.04 |
| 2025-06-13 | 8,273,171 | -9.3% | 902,668 | 9.17 |
| 2025-05-30 | 9,117,810 | -2.2% | 747,034 | 12.21 |
| 2025-05-15 | 9,318,875 | +2.0% | 736,328 | 12.66 |
| 2025-04-30 | 9,137,295 | +30.1% | 1,543,721 | 5.92 |
| 2025-04-15 | 7,022,499 | +1.6% | 1,097,889 | 6.40 |
| 2025-03-31 | 6,909,742 | -1.9% | 656,262 | 10.53 |
| 2025-03-14 | 7,040,446 | +1.7% | 864,815 | 8.14 |
| 2025-02-28 | 6,920,935 | +4.7% | 852,671 | 8.12 |
| 2025-02-14 | 6,612,570 | -15.8% | 727,419 | 9.09 |
| 2025-01-31 | 7,853,734 | -20.4% | 779,354 | 10.08 |
| 2025-01-15 | 9,862,524 | -8.3% | 862,621 | 11.43 |
| 2024-12-31 | 10,749,806 | +5.8% | 1,052,159 | 10.22 |
| 2024-12-13 | 10,161,729 | -3.7% | 869,928 | 11.68 |
| 2024-11-29 | 10,551,873 | -6.1% | 930,619 | 11.34 |
| 2024-11-15 | 11,233,314 | +7.6% | 701,499 | 16.01 |
| 2024-10-31 | 10,443,326 | -3.3% | 642,935 | 16.24 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 3 November 2026, the short share of GPCR volume is 58.4%, up 20.0 points over the last five sessions. Over the last 30 readings it ranged from 15.2% (15 October 2026) to 79.4% (25 September 2026). The latest reading is 23.7 points above the 30-session average of 34.7%, on 266K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-03 | 155K | 266K | 58.4% | 35 |
| 2026-11-02 | 213K | 315K | 67.5% | 0 |
| 2026-10-30 | 119K | 333K | 35.9% | 0 |
| 2026-10-29 | 78K | 298K | 26.1% | 0 |
| 2026-10-28 | 96K | 446K | 21.5% | 200 |
| 2026-10-27 | 137K | 356K | 38.4% | 0 |
| 2026-10-26 | 176K | 342K | 51.5% | 0 |
| 2026-10-23 | 148K | 400K | 37.0% | 150 |
| 2026-10-22 | 111K | 271K | 40.9% | 0 |
| 2026-10-21 | 165K | 429K | 38.6% | 0 |
| 2026-10-20 | 175K | 763K | 22.9% | 260 |
| 2026-10-19 | 161K | 520K | 31.0% | 5,405 |
| 2026-10-16 | 77K | 453K | 17.0% | 0 |
| 2026-10-15 | 83K | 546K | 15.2% | 1,300 |
| 2026-10-14 | 135K | 866K | 15.6% | 0 |
| 2026-10-13 | 180K | 747K | 24.1% | 16 |
| 2026-10-12 | 176K | 905K | 19.4% | 0 |
| 2026-10-09 | 97K | 241K | 40.2% | 0 |
| 2026-10-08 | 121K | 409K | 29.5% | 0 |
| 2026-10-07 | 153K | 499K | 30.7% | 389 |
| 2026-10-06 | 256K | 677K | 37.8% | 0 |
| 2026-10-05 | 172K | 578K | 29.8% | 800 |
| 2026-10-02 | 197K | 700K | 28.1% | 4,000 |
| 2026-10-01 | 158K | 863K | 18.3% | 0 |
| 2026-09-30 | 266K | 881K | 30.2% | 10 |
| 2026-09-29 | 208K | 413K | 50.4% | 0 |
| 2026-09-28 | 161K | 381K | 42.2% | 0 |
| 2026-09-25 | 707K | 891K | 79.4% | 0 |
| 2026-09-24 | 174K | 707K | 24.6% | 0 |
| 2026-09-23 | 189K | 495K | 38.2% | 144 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in GPCR is 3,299 shares, up 2,387 shares over the last settlement date. Over the last 30 readings it ranged from 6 shares (2 April 2026) to 152,914 shares (13 April 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 3,299 | $22.31 | $74K |
| 2026-10-13 | 912 | $23.91 | $22K |
| 2026-10-09 | 30 | $25.67 | $770 |
| 2026-10-02 | 2,000 | $28.98 | $58K |
| 2026-10-01 | 9,578 | $31.27 | $300K |
| 2026-08-27 | 24 | $49.35 | $1K |
| 2026-07-17 | 495 | $46.03 | $23K |
| 2026-07-10 | 1,000 | $55.14 | $55K |
| 2026-07-08 | 580 | $56.63 | $33K |
| 2026-07-02 | 2,260 | $52.12 | $118K |
| 2026-07-01 | 500 | $53.67 | $27K |
| 2026-06-30 | 3,611 | $51.69 | $187K |
| 2026-06-22 | 150 | $44.51 | $7K |
| 2026-06-15 | 329 | $42.93 | $14K |
| 2026-06-11 | 2,227 | $41.53 | $92K |
| 2026-06-08 | 4,181 | $37.58 | $157K |
| 2026-05-26 | 495 | $39.19 | $19K |
| 2026-04-28 | 43 | $45.33 | $2K |
| 2026-04-23 | 605 | $46.50 | $28K |
| 2026-04-15 | 111,564 | $53.22 | $5.9M |
| 2026-04-14 | 176 | $54.25 | $10K |
| 2026-04-13 | 152,914 | $54.51 | $8.3M |
| 2026-04-02 | 6 | $50.17 | $301 |
| 2026-03-20 | 19 | $50.46 | $959 |
| 2026-02-06 | 23,325 | $73.21 | $1.7M |
| 2026-01-29 | 11 | $89.05 | $980 |
| 2026-01-27 | 51 | $89.57 | $5K |
| 2026-01-22 | 709 | $93.79 | $66K |
| 2026-01-20 | 3,300 | $88.64 | $293K |
| 2026-01-16 | 54 | $85.02 | $5K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for GPCR in the last 90 days. The most recent filings are listed below. Latest filing: Coll Crespo Blas (CHIEF MEDICAL OFFICER) on 2026-09-21.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-21 | Coll Crespo Blas | CHIEF MEDICAL OFFICER | Conversion | 12K | $0.00 | $0 | 258K |
| 2026-09-18 | Coll Crespo Blas | CHIEF MEDICAL OFFICER | Tax withholding | 11K | $11.67 | $124K | 270K |
| 2026-09-01 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Conversion | 18K | $0.00 | $0 | 229K |
| 2026-09-01 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Exercise or conversion | 18K | $0.34 | $6K | 247K |
| 2026-08-18 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Conversion | 12K | $0.00 | $0 | 229K |
| 2026-08-18 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Exercise or conversion | 12K | $0.34 | $4K | 241K |
| 2026-08-06 | Berrios John Joseph | Chief Commercial Officer | Grant | 141K | $0.00 | $0 | 141K |
| 2026-08-04 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Conversion | 12K | $0.00 | $0 | 229K |
| 2026-08-04 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Exercise or conversion | 12K | $0.34 | $4K | 241K |
| 2026-07-14 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Conversion | 24K | $0.00 | $0 | 229K |
| 2026-07-14 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Exercise or conversion | 24K | $0.34 | $8K | 253K |
| 2026-06-25 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Conversion | 24K | $0.00 | $0 | 229K |
| 2026-06-25 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Exercise or conversion | 24K | $0.34 | $8K | 253K |
| 2026-04-15 | Lang Matthew | COO & GC | Grant | 185K | $0.00 | $0 | 185K |
| 2026-03-19 | Yoon Jun | CHIEF FINANCIAL OFFICER | Grant | 104K | $0.00 | $0 | 1.4M |
| 2026-03-19 | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | Grant | 260K | $0.00 | $0 | 1.4M |
| 2026-03-19 | Ma Yingli | CHIEF TECHNOLOGY OFFICER | Grant | 33K | $0.00 | $0 | 140K |
| 2026-03-19 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Grant | 43K | $0.00 | $0 | 229K |
| 2026-03-19 | Hall Ashley | Chief Development Officer | Grant | 48K | $0.00 | $0 | 155K |
| 2026-03-19 | Coll Crespo Blas | CHIEF MEDICAL OFFICER | Grant | 76K | $0.00 | $0 | 281K |
| 2026-03-03 | Yoon Jun | CHIEF FINANCIAL OFFICER | Tax withholding | 22K | $20.99 | $468K | 1.3M |
| 2026-03-03 | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | Tax withholding | 53K | $20.99 | $1.1M | 1.1M |
| 2026-03-03 | Ma Yingli | CHIEF TECHNOLOGY OFFICER | Tax withholding | 11K | $20.99 | $237K | 107K |
| 2026-03-03 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Tax withholding | 19K | $20.99 | $393K | 186K |
| 2026-03-03 | Hall Ashley | Chief Development Officer | Tax withholding | 5K | $20.99 | $102K | 107K |
| 2026-03-03 | Coll Crespo Blas | CHIEF MEDICAL OFFICER | Tax withholding | 12K | $20.99 | $248K | 205K |
| 2025-09-18 | Hall Ashley | Chief Development Officer | Tax withholding | 6K | $7.74 | $47K | 112K |
| 2025-09-18 | Coll Crespo Blas | CHIEF MEDICAL OFFICER | Tax withholding | 8K | $7.74 | $63K | 217K |
| 2025-07-01 | Yoon Jun | CHIEF FINANCIAL OFFICER | Tax withholding | 7K | $6.84 | $48K | 1.3M |
| 2025-07-01 | Yoon Jun | CHIEF FINANCIAL OFFICER | Grant | 40K | $0.00 | $0 | 1.3M |
| 2025-07-01 | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | Tax withholding | 16K | $6.84 | $110K | 1.2M |
| 2025-07-01 | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | Grant | 90K | $0.00 | $0 | 1.2M |
| 2025-07-01 | Ma Yingli | CHIEF TECHNOLOGY OFFICER | Grant | 24K | $0.00 | $0 | 123K |
| 2025-07-01 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Grant | 57K | $0.00 | $0 | 217K |
| 2025-07-01 | Coll Crespo Blas | CHIEF MEDICAL OFFICER | Tax withholding | 1K | $6.84 | $10K | 225K |
| 2025-07-01 | Coll Crespo Blas | CHIEF MEDICAL OFFICER | Grant | 8K | $0.00 | $0 | 226K |
| 2025-07-01 | Ma Yingli | CHIEF TECHNOLOGY OFFICER | Tax withholding | 4K | $6.84 | $31K | 119K |
| 2025-07-01 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Tax withholding | 13K | $6.84 | $88K | 204K |
| 2025-03-15 | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | Grant | 340K | $0.00 | $0 | 1.1M |
| 2025-03-15 | Yoon Jun | CHIEF FINANCIAL OFFICER | Grant | 170K | $0.00 | $0 | 1.3M |
| 2025-03-15 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Grant | 81K | $0.00 | $0 | 167K |
| 2025-03-15 | Ma Yingli | CHIEF TECHNOLOGY OFFICER | Grant | 64K | $0.00 | $0 | 101K |
| 2025-03-15 | Hall Ashley | Chief Development Officer | Grant | 51K | $0.00 | $0 | 118K |
| 2025-03-15 | Coll Crespo Blas | Chief Medical Officer | Grant | 117K | $0.00 | $0 | 220K |
| 2025-03-01 | Yoon Jun | CHIEF FINANCIAL OFFICER | Tax withholding | 6K | $7.92 | $47K | 1.3M |
| 2025-03-01 | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | Tax withholding | 12K | $7.92 | $99K | 1.1M |
| 2025-03-01 | Ma Yingli | CHIEF TECHNOLOGY OFFICER | Tax withholding | 2K | $7.92 | $14K | 99K |
| 2025-03-01 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Tax withholding | 6K | $7.92 | $51K | 160K |
| 2025-03-01 | Coll Crespo Blas | CHIEF MEDICAL OFFICER | Tax withholding | 1K | $7.92 | $10K | 218K |
| 2024-09-18 | Coll Crespo Blas | Chief Medical Officer | Grant | 91K | $0.00 | $0 | 103K |
| 2024-09-18 | Hall Ashley | Chief Development Officer | Grant | 67K | $0.00 | $0 | 67K |
| 2024-06-12 | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | Exercise or conversion | 100K | $0.39 | $39K | 743K |
| 2024-06-12 | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | Exercise or conversion | 50K | $0.48 | $24K | 793K |
| 2024-06-10 | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | Conversion | 555K | $0.00 | $0 | 643K |
| 2024-06-03 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Conversion | 106K | $0.00 | $0 | 86K |
| 2024-06-03 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Exercise or conversion | 106K | $0.34 | $36K | 192K |
| 2024-03-15 | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | Grant | 135K | $0.00 | $0 | 1.2M |
| 2024-03-15 | Yoon Jun | CHIEF FINANCIAL OFFICER | Grant | 59K | $0.00 | $0 | 1.1M |
| 2024-03-15 | Bach Mark Allen | CHIEF MEDICAL OFFICER | Grant | 26K | $0.00 | $0 | 26K |
| 2024-03-15 | Ma Yingli | CHIEF TECHNOLOGY OFFICER | Grant | 37K | $0.00 | $0 | 37K |
| 2024-03-15 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | Grant | 86K | $0.00 | $0 | 86K |
| 2023-05-10 | BIOTECHNOLOGY VALUE FUND L P | Other | Other transaction | 2.9M | price not stated in the filing | not stated | 0 |
| 2023-05-10 | BIOTECHNOLOGY VALUE FUND L P | Other | Other transaction | 4.0M | price not stated in the filing | not stated | 0 |
| 2023-05-10 | BIOTECHNOLOGY VALUE FUND L P | Other | Other transaction | 463K | price not stated in the filing | not stated | 0 |
| 2023-02-07 | FIL Ltd | Other | Conversion | 494K | price not stated in the filing | not stated | 494K |
| 2023-02-07 | FIL Ltd | Other | Conversion | 624K | price not stated in the filing | not stated | 624K |
| 2023-02-07 | FIL Ltd | Other | Conversion | 453K | price not stated in the filing | not stated | 5.1M |
| 2023-02-07 | FIL Ltd | Other | Conversion | 7K | price not stated in the filing | not stated | 89K |
| 2023-02-07 | FIL Ltd | Other | Conversion | 10K | price not stated in the filing | not stated | 82K |
| 2023-02-07 | FIL Ltd | Other | Conversion | 72K | price not stated in the filing | not stated | 72K |
| 2023-02-07 | FIL Ltd | Other | Conversion | 179K | price not stated in the filing | not stated | 5.3M |
| 2023-02-07 | FIL Ltd | Other | Conversion | 620K | price not stated in the filing | not stated | 4.6M |
| 2023-02-07 | FIL Ltd | Other | Conversion | 4.0M | price not stated in the filing | not stated | 4.0M |
| 2023-02-07 | FMR LLC | Other | Conversion | 58K | price not stated in the filing | not stated | 58K |
| 2023-02-07 | FMR LLC | Other | Conversion | 965K | price not stated in the filing | not stated | 965K |
| 2023-02-07 | FMR LLC | Other | Conversion | 7K | price not stated in the filing | not stated | 82K |
| 2023-02-07 | FMR LLC | Other | Conversion | 215K | price not stated in the filing | not stated | 4.8M |
| 2023-02-07 | FMR LLC | Other | Conversion | 415K | price not stated in the filing | not stated | 4.6M |
| 2023-02-07 | FMR LLC | Other | Conversion | 568K | price not stated in the filing | not stated | 4.1M |
| 2023-02-07 | FMR LLC | Other | Conversion | 10K | price not stated in the filing | not stated | 68K |
| 2023-02-07 | FMR LLC | Other | Conversion | 7K | price not stated in the filing | not stated | 75K |
| 2023-02-07 | FMR LLC | Other | Conversion | 3.6M | price not stated in the filing | not stated | 3.6M |
| 2023-02-07 | Farid Ramy | Director | Conversion | 642K | price not stated in the filing | not stated | 3.3M |
| 2023-02-07 | WELCH DANIEL G | Director | Conversion | 124K | price not stated in the filing | not stated | 124K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON2 Form 144 notices on file for GPCR worth $1.9M at the prices reported; 1 in the last 90 days worth $140K. Latest: BLAS COLL CRESPO filed on 2026-09-21 to sell 4,008 shares ($140K) from 2026-09-21.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-21 | BLAS COLL CRESPOOfficer | 4K | $140K | 0.002% | 2026-09-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-25 | XICHEN LINOfficer | 36K | $1.7M | 0.017% | 2026-06-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON12 holders report 5% or more of GPCR in their latest filing, all on Schedule 13G (passive). The largest reported stake is FMR LLC at 13.2% of the class (28,197,369 shares), filed 2026-08-06 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-06 | 13G/Ano. 6 | FMR LLCparent holding company | 28.2M | 13.2% | 2026-06-30 |
| 2026-08-06 | 13G/Ano. 6 | Abigail P. Johnsonindividual | 28.2M | 13.2% | 2026-06-30 |
| 2026-02-17 | 13G/Ano. 1 | BVF INC/ILcorporation | 10.4M | 4.9% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | LAMPERT MARK Nindividual | 10.4M | 4.9% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | BVF PARTNERS L P/ILinvestment adviser, partnership | 10.4M | 4.9% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | BVF GP HOLDINGS LLCother entity | 9.6M | 4.5% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | BIOTECHNOLOGY VALUE FUND L Ppartnership | 5.6M | 2.6% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | BVF I GP LLCother entity | 5.6M | 2.6% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | BVF II GP LLCother entity | 4.1M | 1.9% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | BIOTECHNOLOGY VALUE FUND II LPpartnership | 4.1M | 1.9% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | BVF Partners OS Ltd.corporation | 644K | 0.3% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Biotechnology Value Trading Fund OS LPpartnership | 644K | 0.3% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 4 | Deep Track Capital, LPinvestment adviser, other entity | 12.3M | 6.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 4 | Deep Track Biotechnology Master Fund, Ltd.corporation | 12.3M | 6.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 4 | David Kroinparent holding company, individual | 12.3M | 6.0% | 2025-12-31 |
| 2026-02-10 | 13G/Ano. 6 | Wellington Investment Advisors Holdings LLPparent holding company | 21.4M | 10.1% | 2025-12-31 |
| 2026-02-10 | 13G/Ano. 6 | Wellington Management Group LLPparent holding company | 21.4M | 10.1% | 2025-12-31 |
| 2026-02-10 | 13G/Ano. 6 | Wellington Group Holdings LLPparent holding company | 21.4M | 10.1% | 2025-12-31 |
| 2026-02-10 | 13G/Ano. 6 | Wellington Management Company LLPinvestment adviser | 21.4M | 9.6% | 2025-12-31 |
| 2025-11-14 | 13G/Ano. 4 | JANUS HENDERSON GROUP PLCinvestment adviser, parent holding company | 4.4M | 7.7% | 2025-09-30 |
| 2025-11-14 | 13G | Avoro Capital Advisors LLCinvestment adviser, other entity | 16.2M | 9.4% | 2025-09-30 |
| 2025-11-14 | 13G | Aghazadeh Behzadparent holding company, individual | 16.2M | 9.4% | 2025-09-30 |
13F holders
Tracked managers holding GPCR at their latest 13F. JSON3 of the 30 tracked managers held GPCR at their latest 13F, $22.0M in total at quarter-end prices. Two Sigma Investments is the largest at $11.0M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 1 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 204K | $11.0M | 0.01% | +23K |
| D. E. Shaw & Co. | 2026-06-30 | 115K | $6.2M | 0.00% | -89K |
| Millennium Management | 2026-06-30 | 90K | $4.8M | 0.00% | -79K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Structure Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Structure Therapeutics (GPCR), SEC CIK 1888886, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-03.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-21.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-06.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-21.JSON and CSV
- Company record
- EDGAR filing index for CIK 1888886Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of GPCR is sold short?
7,147,328 shares were held short at the 2026-10-15 settlement, 4.8 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is GPCR's daily short volume?
On 2026-11-03, 155,461 of the 266,199 GPCR shares reported to FINRA were sold short, 58.4% of the day's reported volume. Short volume is a flow for one day, not a position.
Does GPCR have fails to deliver?
The SEC's latest file shows 3,299 GPCR shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are GPCR insiders buying or selling?
No open-market insider trades were reported for GPCR in the last 90 days. The most recent filings are listed below. Latest filing: Coll Crespo Blas (CHIEF MEDICAL OFFICER) on 2026-09-21.
Have GPCR insiders filed to sell?
2 Form 144 notices on file for GPCR worth $1.9M at the prices reported; 1 in the last 90 days worth $140K. Latest: BLAS COLL CRESPO filed on 2026-09-21 to sell 4,008 shares ($140K) from 2026-09-21.
Who owns 5% or more of GPCR?
12 holders report 5% or more of GPCR in their latest filing, all on Schedule 13G (passive). The largest reported stake is FMR LLC at 13.2% of the class (28,197,369 shares), filed 2026-08-06 for an event on 2026-06-30.
Which tracked 13F managers own GPCR?
3 of the 30 tracked 13F managers held GPCR shares at their latest filing, $22.0M in all. The largest: Two Sigma Investments (204K shares, $11.0M), D. E. Shaw & Co. (115K shares, $6.2M), Izzy Englander's Millennium Management (90K shares, $4.8M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.